Input 2020.12.14 08:22
–
Sinoparm was conducting a clinical trial in Peru with 12,000 participants, and the trial was expected to be completed within a few days.
However, as one participant struggled to use his leg, Peruvian health authorities decided to stop the test.
A Peruvian health official said the participant had symptoms similar to Guillain-Barre syndrome.
Guillain-Barre syndrome is an unknown cause of inflammation in the peripheral nerves, mainly causing pain and paralysis in the limbs. It appears at a frequency of 10 to 20 per year per million adults, and there are cases of influenza (influenza) vaccine side effects.
It was not disclosed which type of synopam vaccine was used in this trial.
China has said that 1 million people in their country have been vaccinated with the sinofam vaccine, but no side effects have been reported.
However, it is causing concern from medical officials around the world as detailed data including infection cases, which are the basis for the estimation of efficacy, have not been disclosed.
Synofam vaccine is currently undergoing clinical trials in Argentina, Bahrain, Egypt, Indonesia, Jordan, Morocco, and Russia, and vaccination has begun in Egypt and Indonesia. On the 8th, the UAE government officially approved the use.
–
– .
